

On-line Table: Comparison of key outcomes (efficacy and safety) among trials

	ESCAPE		MR CLEAN		SWIFT-PRIME		EXTEND-IA		REVASCAT	
	Treatment Group	Control Group	Treatment Group	Control Group	Treatment Group	Control Group	Treatment Group	Control Group	Treatment Group	Control Group
mRS score at 90 days (median)	2	4	3 (2-5)	4 (3-5)	2 (1-4)	3 (2-5)	1 (0-3)	3 (1-5)	NA	NA
	Adjusted common odds ratio = 3.1	Adjusted common odds ratio = 1.67	Adjusted common odds ratio = 1.67	Adjusted common odds ratio = 1.67	$P < .001$	$P < .001$	Adjusted common odds ratio = 2	Adjusted common odds ratio = 1.7	Adjusted common odds ratio = 1.7	Adjusted common odds ratio = 1.7
NNT	3.1	7	7	7	2.6	2.6	3	3	NA	NA
mRS 0-2 at 90 days	53%	29.3%	32.6%	19.1%	60%	35%	71%	40%	43.7%	28.2%
	$P < .001$	$P < .001$			$P < .001$	$P < .001$	$P = .01$			
Revascularization rates	3.6%	2.7%	7.7%	6.4%	0%	3%	0%	6%	1.9%	19%
SICH	72.4%	72.4%	58.7%	58.7%	88%	88%	86.2%	86.2%	65.7%	65.7%
	$P = .75$	$P = .75$			$P = .12$	$P = .12$	$P = .49$	$P = .49$		
Mortality	10.4%	19%	18.9%	18.4%	9%	12%	9%	20%	18.4%	15.5%
	At 90 days, $P = .04$	At 90 days, $P = .04$	At 30 days, 11.1%	At 30 days, 11.1%	At 90 days, $P = .50$	At 90 days, $P = .50$	$P = .18$	$P = .18$		
Procedural nonfatal complications	11.9%	11.9%	11.1%	11.1%	7.1%	7.1%	14%	14%	29.4%	29.4%

Note:—NNT indicates number needed to treat; SICH, symptomatic intracerebral hemorrhage; NA, not applicable.